{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["13(8)"],"submitter":["Nguyen NT"],"pubmed_abstract":["Despite evidence of SGLT2 inhibitors in improving cardiovascular outcomes of heart failure with preserved ejection fraction (HFpEF), the heterogenous mechanism and characteristic multimorbidity of HFpEF require a phenotypic approach. Metabolic phenotype, one common HFpEF phenotype, has various presentations and prognoses worldwide. We aimed to identify different phenotypes of hypertensive-diabetic HFpEF, their phenotype-related outcomes, and treatment responses. The primary endpoint was time to the first event of all-cause mortality or hospitalization for heart failure (HHF). Among 233 recruited patients, 24.9% experienced primary outcomes within 12 months. A total of 3.9% was lost to follow-up. Three phenotypes were identified. Phenotype 1 (n = 126) consisted of lean, elderly females with"],"journal":["Journal of personalized medicine"],"pagination":["1218"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10455077"],"repository":["biostudies-literature"],"pubmed_title":["Phenotype-Specific Outcome and Treatment Response in Heart Failure with Preserved Ejection Fraction with Comorbid Hypertension and Diabetes: A 12-Month Multicentered Prospective Cohort Study."],"pmcid":["PMC10455077"],"pubmed_authors":["Nguyen HH","Truong BQ","Nguyen NT","Nguyen HA","Chau HN"],"additional_accession":[]},"is_claimable":false,"name":"Phenotype-Specific Outcome and Treatment Response in Heart Failure with Preserved Ejection Fraction with Comorbid Hypertension and Diabetes: A 12-Month Multicentered Prospective Cohort Study.","description":"Despite evidence of SGLT2 inhibitors in improving cardiovascular outcomes of heart failure with preserved ejection fraction (HFpEF), the heterogenous mechanism and characteristic multimorbidity of HFpEF require a phenotypic approach. Metabolic phenotype, one common HFpEF phenotype, has various presentations and prognoses worldwide. We aimed to identify different phenotypes of hypertensive-diabetic HFpEF, their phenotype-related outcomes, and treatment responses. The primary endpoint was time to the first event of all-cause mortality or hospitalization for heart failure (HHF). Among 233 recruited patients, 24.9% experienced primary outcomes within 12 months. A total of 3.9% was lost to follow-up. Three phenotypes were identified. Phenotype 1 (n = 126) consisted of lean, elderly females with","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Jul","modification":"2026-06-23T03:13:34.045Z","creation":"2025-04-07T10:22:20.049Z"},"accession":"S-EPMC10455077","cross_references":{"pubmed":["37623468"],"doi":["10.3390/jpm13081218"]}}